A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors

Protocol No
SOTIO-BOXR1030
Phase
I/II
Summary

This study is designed to test the safety of giving BOXR1030 to patients who have cancer that expresses GPC3

Description
BOXR1030 T Cells in Advanced GPC3-Positive Solid Tumors
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Gastrointestinal Cancers, Lung, Thoracic Cancers, Sarcoma
ClinicalTrials.gov
go to website